NASD · Healthcare · Diagnostics & Research · USA
Caredx Inc is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
CareDx develops diagnostic testing and digital solutions for transplant patients and centers. The company offers blood-based tests to detect organ rejection in heart, kidney, and lung recipients, along with pre-transplant products and pharmacy services. Operating laboratories in California, Nebraska, and Sweden, CareDx serves transplant facilities across the United States and Europe.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Caredx Inc stock.
Overvalued: intrinsic value $41.86 per share, market price $67.08, margin of safety -60.2% (as of 2026-10-19).
A 4.0x revenue multiple, discounted for its losses, values the shares at $41.86; the price of $67.08 is 60% above that value.
Leak Score: 52/100 on 10 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
4 more in this industry show a wider margin of safety.
CDNA is overvalued (as of the 2026-10-19 close). A 4.0x revenue multiple, discounted for its losses, values the shares at $41.86; the price of $67.08 is 60% above that value.
$41.86 per share (as of the 2026-10-19 close), against a market price of $67.08. That is a margin of safety of -60.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
52 out of 100, which we rate "Weak Signal", on 10 of 12 value investing signals.